NCT03145675View on ClinicalTrials.gov

Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)

PHASE4CompletedINTERVENTIONAL

Enrollment

378

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

April 20, 2022

Study Completion Date

July 14, 2022

Conditions

Coronary Artery DiseasePercutaneous Coronary Intervention

Interventions

DRUG

Enoxaparin (Staged-dose PCI Group)

Enoxaparin 0.5+0.25 mg/kg administered intravenously.

DRUG

Enoxaparin (Single-dose PCI Group)

Enoxaparin 0.75 mg/kg administered intravenously.

DRUG

Enoxaparin (High-dose Group)

Enoxaparin 0.75 mg/kg administered intravenously.

DRUG

Enoxaparin (Standard-dose Group)

Enoxaparin 0.5 mg/kg administered intravenously.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER

NCT03145675 - Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI) | Biotech Hunter | Biotech Hunter